Tag: CDMO
Jubilant Biosys to expand its footprint in Europe, add drug discovery...
Through a series of collaborative and acquisition deals, company aims to develop a unique delivery model tailored for its customers
Akums Drugs secures patent for room temperature stable oral suspension of...
This development offers a significant advance in addressing the storage and accessibility challenges associated with Hydroxyurea solution
Influx Healthtech files for IPO on NSE Emerge to expand operations
Mumbai-based CDMO targets growth with new manufacturing facilities in the nutraceutical and veterinary sectors
Enzene appoints Norm Stoffregen to lead new U.S. biomanufacturing facility
Stoffregen will oversee commissioning and expand operations at Enzene's $50 million biologics manufacturing facility in Hopewell, NJ
OneSource and BRL announce licensing agreement on advanced biologics delivery technology
Revolutionary HILOPRO® technology to enhance subcutaneous delivery of high-concentration biologics, boosting OneSource’s scientific services
Navin Molecular invests $35 million to expand GMP manufacturing capabilities
New facility to double capacity and enhance advanced chemistries, create 100 jobs by 2025, supporting global pharmaceutical innovators
Enzene launches discovery services division at BIO 2024
CDMO provides end-to-end drug discovery, development and commercialization services with sites in both the USA and Asia
India Unlimited: ICPA event in San Diego on 2nd June to...
Happening on the sidelines of US BIO 2024, the event will see top experts sharing their perspective on how international stakeholders can benefit from outsourcing their requirements to India
Samsung Biologics set to thrive if BIOSECURE bill passes in US, says...
A list of companies of concern, including the Chinese CDMO giant Wuxi AppTec Ltd., is included in the bill. If the bill passes, the government will examine whether any other China-based companies should be added
Maiva Pharma raises Rs 1,000 Crore from Morgan Stanley Private Equity...
The investors have jointly acquired a controlling stake from existing investors and infused primary capital in the company